3 Questions to Ask Before Your First GLP-1 Dose

Online GLP-1 prescribing exploded over the past year. $99-a-month platforms, two-minute intake forms, next-day shipping. The medication reached more people than ever before — and that, on its own, is good. But it also means the quality of clinical care wrapped around the medication varies wildly from one provider to another.

Before you accept your first prescription for semaglutide or tirzepatide, there are three questions your team should be able to answer without hesitation. If they can’t — or if the answers leave you with more questions than answers — it’s worth pausing before you inject.

These aren’t questions designed to make you afraid of GLP-1s. They’re questions designed to tell you whether the team prescribing it is actually caring for you.

Why These Three Questions, and Not Others

There are lists of twenty questions on the internet. Most of them are useful, and most of them are also too long. These three are chosen on purpose because each measures something different about the care model, not the medication itself.

The first question measures vigilance — whether anyone is actually watching how you respond.

The second measures personalization — whether the plan adjusts to you, or whether everyone gets the same protocol.

The third measures access — whether you can talk to your team in the language you think in, not the one you have to translate into.

If all three are answered well, almost everything else falls into place. If any one is answered badly, there’s a gap in the care that the medication alone can’t fill.

Question 1 — How Do You Monitor Side Effects?

GLP-1 medications are clinically active and, like every clinically active medication, come with side effects. Most are mild — nausea, constipation, fatigue in the early weeks — and tend to improve after the initial titration. A few, much less common, require faster medical attention.¹

The question isn’t “what side effects will I have?” — that varies person to person. The right question is: how will you know if I’m having them, and when?

A strong answer sounds like this:

There is a direct channel to report symptoms — not a generic customer-service number.
Check-ins are scheduled in the first weeks, not only when you ask for them.
Clinical staff read the reports, not a bot answering with templates.
There’s a clear plan for when to escalate to your treating provider, or when to refer you to your primary-care clinician.

A weak answer sounds like this: “you can message us if anything happens.” That puts the entire load on the patient — who often doesn’t know whether what they’re feeling is normal — and leaves the clinical team in reactive rather than preventive mode.

Question 2 — When and How Do You Adjust My Dose?

Titration is what separates a good GLP-1 outcome from a mediocre one. Starting low, climbing gradually, knowing when to hold a dose longer, and knowing when to step down if side effects are intense — all of that is active medical work.²

Ask your team:

What is the initial titration protocol? (A real answer uses numbers — for example, “0.25 mg weekly for four weeks, then review.”)
Under what conditions do you hold the dose instead of stepping up? (Gastrointestinal tolerance, weekly weight, other indicators.)
Who makes the decision to adjust? (Ideally, the same treating provider who evaluated you at intake — not a rotating substitute every month.)
How often is the plan reviewed? (Monthly check-ins for at least the first three months are reasonable.)

A serious team treats your dose as an ongoing conversation, not an automatic refill. If the model is “we’ll send you the same thing every month until you cancel,” that’s not care — that’s logistics.

Question 3 — What Language Do You Speak with Me?

This question sounds basic, and it’s the one most platforms underestimate. For a bilingual patient — and especially for a patient whose medical thinking happens in Spanish — the language in which care happens changes the outcome.

The reason is simple: side effects are described better in your own language. The difference between “I feel dizzy” and “I have constant nausea” is clinically meaningful, and you notice it more when you’re writing in your first language. Nuances around mood, appetite, energy, and digestion don’t translate one-for-one. Research on medical communication shows that patients who receive care in their preferred language report better adherence and less confusion about instructions.³

Concrete questions worth asking:

Does my treating provider speak my language, or do you translate through an interpreter? Both options exist, but they’re not the same thing.
Are written instructions available in my language? Not just the general brochure — your specific plan, too.
Do the portal and support chat work in my language?
Does my coordinator — the person I’ll talk to day-to-day — speak my language?

If any link in that chain only works in one language, that’s friction. Friction translates into questions you don’t ask, symptoms you don’t report, and doses you take without quite understanding them.

How REMEVi Answers These Three Questions

REMEVi was built around these three answers, not as an afterthought.

On monitoring: REMEVi patients have scheduled check-ins at weeks 1, 2, 4, and 8 — plus a direct channel to report symptoms at any point. Those reports are read by your clinical team, not an automated system.

On dose adjustments: your treating provider is the same person who evaluated you at intake. Titration is discussed with you before every step, based on your weight, your gastrointestinal tolerance, and your goals. If side effects are intense, the dose holds or steps down — it isn’t pushed to a fixed target.

On language: REMEVi is bilingual-native, not translated. Your coordinator speaks Spanish and English and communicates with you in the language you write in. The portal, instructions, and educational content exist fully in both languages. If at any point your provider doesn’t speak Spanish, you’ll know before you accept the appointment — not after.

These three answers are why REMEVi prefers to grow more slowly than to compromise the model. Medication is a tool. The bilingual care wrapped around it is what changes the long-term outcome.

Talk to a REMEVi provider →

Frequently Asked Questions

Do these three questions also apply to tirzepatide and other GLP-1s?

Yes. The questions are about the care model, not the molecule. They apply equally to semaglutide, tirzepatide, and any GLP-1 prescribed via telehealth.

What do I do if the team can’t answer them in detail?

That’s a sign to pause. It doesn’t mean the platform is bad — it means it’s worth gathering more information before starting. The medication will still be available a week from now.

Does REMEVi serve patients in languages beyond English and Spanish?

We currently provide full bilingual care in English and Spanish. If your preferred language is something else, we can coordinate interpretation, but we want to be transparent about the scope of our native bilingual model.

How much does the clinical care cost on top of the medication?

Your initial consult, dose adjustments, check-ins, and coordinator support are all included in your monthly treatment price. There are no additional charges for contacting your clinical team.

What if I already started a GLP-1 elsewhere and they didn’t answer these questions?

You can switch providers at any time. Your new medical team reviews your history, your current dose, and builds a continuity plan. You don’t have to start over.

Medical Disclaimer

The information in this article is for educational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are medications that require evaluation and ongoing supervision by a licensed healthcare provider. Individual responses to GLP-1 treatment vary based on genetics, medical history, lifestyle, and other factors. Do not start, stop, or change your medication without consulting your provider. If you experience severe side effects, seek medical care promptly.

References

¹ Wharton S, et al. Postgrad Med. 2022;134(1):14-19 — Clinical management of gastrointestinal effects with GLP-1 receptor agonists. ² Garvey WT, et al. Nat Med. 2022;28:2083-2091 — Individualized titration of GLP-1 receptor agonists and clinical outcomes. ³ Diamond LC, et al. J Gen Intern Med. 2019;34(8):1591-1606 — Patient–provider language concordance and health outcomes.